Follicular lymphoma (FL) is a clinically and genetically heterogeneous disease. We established a clinicogenetic risk model (m7-FLIPI) that improves risk stratification by integrating the mutation status1) of seven genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP and CARD11), the FL International Prognostic Index (FLIPI) and ECOG performance status.
Note, that this score was established and validated only in patients with follicular lymphoma grade 1, 2, or 3A, advanced stage or bulky disease considered ineligible for curative irradiation, symptomatic disease requiring systemic treatment according to published criteria (Hiddemann et al., Blood 2004), and a lymphoma biopsy obtained less than 12 months prior to therapy initiation. All patients received a combination of rituximab and chemotherapy (either CVP or CHOP) as first-line treatment.
In an independent validation cohort, risk stratification by m7-FLIPI outperformed FLIPI alone, and FLIPI combined with ECOG performance status, and identified a high-risk group (24/107, 22% of patients) with 5-year failure-free survival of 25% versus 68% (HR 3.6, 95% CI 2.0 - 6.4, p<0.0001) in the low-risk group.
The m7-FLIPI was published 2015 in Lancet Oncology as by Pastore A et al.
Here you can calculate the m7-FLIPI score and the resulting risk group (high versus low). By using this calculator you accept that GLSG does not assume any liability.
1) any somatic or putative somatic non-silent mutation (i.e. missense mutations, nonsense mutations, in-frame or frame-shift insertions/deletions (InDel), translational start site mutations, or splice site mutations).